Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bedaquiline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,461Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J Reduces Sirturo Price In South Africa, Ending Antitrust Probe
    J&J Reduces Sirturo Price In South Africa, Ending Antitrust Probe

    09 Jul 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jj-agrees-40-price-cut-tuberculosis-med-sirturo-south-africa-ending-antitrust-probe

    FIERCE PHARMA
    09 Jul 2024
    Share Share
    J&J's tuberculosis Sirturo lands full US, EU approvals
    J&J's tuberculosis Sirturo lands full US, EU approvals

    08 Jul 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jjs-tuberculosis-med-sirturo-lands-full-us-european-approvals-after-more-decade

    FIERCE PHARMA
    08 Jul 2024
    Share Share
    Janssen Submits Phase 3 Study Data to the EMA and FDA for SIRTURO
    Janssen Submits Phase 3 Study Data to the EMA and FDA for SIRTURO

    07 Nov 2023

    // PRESS RELEASE

    https://www.jnj.com/janssen-submits-phase-3-study-data-to-the-european-medicines-agency-and-u-s-food-and-drug-administration-for-sirturo-bedaquiline

    PRESS RELEASE
    07 Nov 2023
    Share Share
    After pubic pressure, J&J says it won't enforce Sirturo patents
    After pubic pressure, J&J says it won't enforce Sirturo patents

    02 Oct 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/johnson-johnson-commits-not-enforce-secondary-patents-tuberculosis-med-sirturo

    Zoey Becker FIERCE PHARMA
    02 Oct 2023
    Share Share
    J&J, Lupin reduce price of TB drug bedaquiline in poor countries
    J&J, Lupin reduce price of TB drug bedaquiline in poor countries

    01 Sep 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/johnson-johnson-slashes-price-tuberculosis-drug-sirturo-after-relinquishing-patent

    Kevin Dunleavy FIERCE PHARMA
    01 Sep 2023
    Share Share
    J&J loses attempt to extend patent in India for tuberculosis drug
    J&J loses attempt to extend patent in India for tuberculosis drug

    23 Mar 2023

    // ENDPTS

    https://endpts.com/jj-loses-attempt-to-extend-patent-in-india-for-tuberculosis-drug/

    ENDPTS
    23 Mar 2023
    Share Share